Article
Outcomes of adjuvant epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutant non-small-cell lung cancer: a propensity-score analysis.
Scientific reports - 14 Sept 2017
Zhao Shufen, Ma Ge, Guo Jing, Ding Aiping, Wang Shasha, Yu Guohong, Chen Lei, Yuan Yonggang, Xiao Wenjing
Abstract excerpt
Small molecule tyrosine kinase inhibitors (TKIs) have transformed the management of advanced non-small-cell lung cancer (NSCLC) harboring activating epithelial growth factor receptor (EGFR) mutations, while the efficacy of TKIs in the adjuvant setting remains unclear. We collected the data of 209 EGFR-mutant NSCLC patients receiving complete resection from 2010 to 2013. Study end points were disease-free survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.